Affiliation:
1. Department of Radiology, Faculty of Medicine, Kagawa University, Miki-cho 761-0793, Japan
2. Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho 761-0793, Japan
Abstract
Background: Identifying programmed death-ligand-1 (PD-L1) expression is crucial for optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of intratumoral metabolic heterogeneity specifically derived from 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) images in predicting PD-L1 expression in patients with newly diagnosed non-small cell lung cancer (NSCLC) remains unexplored. Here, we investigated the association between FDG PET texture features and PD-L1 expression by retrospectively analyzing the data of patients newly diagnosed with NSCLC who underwent FDG PET/CT scans and PD-L1 immunohistochemical staining before treatment. Methods: Patients were categorized based on their tumor proportion scores (TPSs) into negative-, low-, and high-PD-L1 expression groups. We computed the maximum standardized uptake value and 31 texture features for the primary tumor from PET images and compared differences in parameters among the groups. Results: Of the 83 patients, 12, 45, and 26 were assigned to the negative-, low-, and high-PD-L1 expression groups, respectively. Six specific texture features (low gray-level run emphasis, short-run low gray-level emphasis, long-run high gray-level emphasis, low gray-level zone emphasis, high gray-level zone emphasis, and short-zone low gray-level emphasis) helped distinguish among all possible combinations. Conclusions: Our findings revealed that FDG PET texture features are potential imaging biomarkers for predicting PD-L1 expression in patients newly diagnosed with NSCLC.
Funder
Japan Society for the Promotion of Science
Reference28 articles.
1. Lung cancer;Thai;Lancet,2021
2. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N. Engl. J. Med.,2016
3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019
4. Non-small cell lung cancer: Recommendations for biomarker testing and treatment;Aisner;J. Natl. Compr. Cancer Netw.,2021
5. Image-derived biomarkers and multimodal imaging strategies for lung cancer management;Sauter;Eur. J. Nucl. Med. Mol. Imaging,2015